Law360, New York (September 3, 2010, 2:25 PM EDT) -- Ranbaxy Laboratories Ltd. has admitted that its proposed generic version of the antiviral drug Valcyte would infringe a patent asserted by Roche Palo Alto LLC and plans to launch its generic product no later than March 2013, pursuant to a settlement that resolves litigation Roche brought against Ranbaxy in 2006.
Judge Freda L. Wolfson of the U.S. District Court for the District of New Jersey signed off on an order Aug. 26 dismissing the case with prejudice.
Judge Wolfson also vacated a September 2009 order that...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.